至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

A novel bispecific antibody, S-Fab, induces potent cancer cell killing.

J. Immunother.. 2019; 
Li Li,He Ping,Zhou Changhua,Jing Li,Dong Bin,Chen Siqi,Zhang Ning,Liu Yawei,Miao Ji,Wang Zhong,Li
Products/Services Used Details Operation
Gene Synthesis The VH and VL of anti-CD3 (humanized UCHT1)20 and the camel anti-CEA VHH21 were directly synthesized (Genscript) and cloned into the pET21a or pET26b plasmid. Get A Quote

摘要

Bispecific antibodies that engage immune cells to kill cancer cells have been actively studied in cancer immunotherapy. In this study, we present a novel bispecific format, S-Fab, fabricated by linking a single-domain anti-carcinoembryonic antigen VHH to a conventional anti-CD3 Fab. In contrast to most bispecific antibodies, the S-Fab bispecific antibody can be efficiently expressed and purified from bacteria. The purified S-Fab is stable in serum and is able to recruit T cells to drive potent cancer cell killing. In xenograft models, the S-Fab antibody suppresses tumor growth in the presence of human immune cells. Our study suggested that the bispecific S-Fab format can be applied to a wide range of ... More

关键词